Personalis expands Tempus AI strategic collaboration
Don't Miss TipRanks' Half-Year Sale
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Delta Announces AGM Results
Toronto, Ontario--(Newsfile Corp. - August 15, 2025) - Delta Resources Limited (TSXV: DLTA) (OTC Pink: DTARF) (FSE: 6GO1) ("Delta" or "the Company") is pleased to announce the results of voting at its Annual and Special Meeting of shareholders held on Thursday, August 14, 2025. Shareholders voted in favour of all items put forward by the Board of Directors and Management. Frank Candido, Kevin B. Heather, Justin Reid and Sara Marcotte Paquet were all re-elected as Directors of the Company and Ronald Kopas was elected as a Director of the Company. The shareholders appointed Raymond Chabot Grant Thornton LLP as auditors of the Company and approved the Company's Omnibus Equity Incentive Plan. ON BEHALF OF THE BOARD OF DELTA RESOURCES LIMITED. Frank CandidoChairman of the About Delta Resources Limited Delta Resources is a Canadian mineral exploration company focused on its Delta-1 project in Ontario, Canada, where the Company discovered a large gold deposit 50 km west of Thunder Bay, at surface and adjacent to the Trans-Canada highway. To date, the gold deposit is 2.5 km long, from surface to 300 m depth. Highlights include drill intercepts such as 5.92 g/t Au over 31 m (incl. 14.8 g/t Au over 11.9 m), and 1.79 g/t Au over 128.5 m. The property covers 297 square kilometres where Delta has identified multiple corridors of intense alteration and deformation, on strike with, and to the south of the Eureka gold zone and that has yet to be thoroughly explored. For Further Information: Contact Delta Resources Limited Frank Candido, ChairmanTel: 514-969-5530fcandido@ Kopas, CEOrkopas@ We seek safe harbor. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. The TSX Venture Exchange has not approved nor disapproved of the information contained herein. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
a day ago
- Business Insider
Cathie Wood's ARK Investment buys 133.3K shares of Personalis today
20:16 EDT Cathie Wood's ARK Investment buys 133.3K shares of Personalis (PSNL) today Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Medscape
2 days ago
- Medscape
Out-of-Pocket Prep Costs Reduce Screening Colonoscopy Uptake
Out-of-pocket costs for bowel preparation are deterring people, especially vulnerable and underserved groups, from colonoscopy for colorectal cancer (CRC) screening, a large insurance-claims analysis in Gastroenterology reported. Moreover, this cost-sharing contravenes the preventive-care provisions for bowel preparation mandated by the Affordable Care Act (ACA). Led by Gastroenterologist Eric D. Shah, MD, MBA, a clinical associate professor at the University of Michigan in Ann Arbor, Michigan, the study found a significant proportion of prescribed bowel preparation claims — 53% for commercial plans and 83% for Medicare — still involve patient cost-sharing, indicating noncompliance with ACA guidelines. Although expense-sharing was less prevalent among Medicaid claims (just 27%), it was not eliminated, suggesting room for improvement in coverage enforcement across the board. 'Colon cancer is unique in that it can be prevented with colonoscopy, but where are the patients? Bowel prep is a major reason that patients defer screening,' Shah told Medscape Medical News. He said his group was quite surprised that the majority in the study cohort were paying something out of pocket when these costs should have been covered. 'Primary care doctors may not think to ask about bowel prep costs when they order screening colonoscopies.' The findings emerged from an analysis of 2,593,079 prescription drug claims: 52.9% from commercial plans, 35% from Medicare Part D plans, and 8.3% from Medicaid plans. 'These patient costs of $30 or $50 are a real not a theoretical deterrent,' said Whitney Jones, MD, a gastroenterologist, adjunct clinical professor at the University of Louisville in Louisville, Kentucky, and founder of the nonprofit colon cancer prevention project. Jones was not involved in the analysis. 'Some insurers require prior patient authorization for the low-dose preps, but gastroenterologists are doing so many colonoscopies they don't always have time to get a PA [prior authorization] on everyone.' With the increasing use of blood and stool-based CRC testing, he added, 'when you get a positive result, it's really important to have the procedure quickly.' And appropriate bowel preparation is a small, cost-effective portion of the total costs of colonoscopy, a procedure that ultimately saves insurers significant money in treatment costs. The authors noted that while CRC is the second-leading cause of cancer-related deaths in the US, screening rates remain low, with only 59% of adults aged 45 years or older up to date with screening. Screening rates are particularly low among racial and ethnic minority groups as compared with White individuals, a disparity that highlights the need to address existing barriers and enhance screening efforts. In the current study, shared costs by bowel preparation volume also varied. Low-volume formulations had consistently higher out-of-pocket costs: a median of $60 for low-volume vs $10 for high-volume in commercial plans. In Medicare, 75% of high-volume claims had shared costs compared with 90% for their low-volume counterparts. The cost-sharing difference was slightly narrower with Medicaid: 27% of high-volume claims vs 30% of low-volume claims. This is concerning, as low-volume options, which are preferred by patients for their better tolerability, can enhance uptake and adherence and improve colonoscopy outcomes. Shah advises physicians to consider prescribing low-volume preparations. 'Let patients know about the potential out-of-pocket cost and about copay cards and assistance programs and use high-volume preps as an alternative rather than a go-to,' he said. As to costs across insurance types, among commercial plans, the median nonzero out-of-pocket cost was $10 for high-volume and $60 for low-volume product claims. For Medicare, the median nonzero out-of-pocket cost was $8 for high-volume and $55.99 for low-volume products. Under the ACA, CRC screening is classified as a recommended preventive service, requiring health plans to cover it without cost-sharing. Although the Centers for Medicare & Medicaid Services previously tried to enforce this mandate in 2015 and 2016, stating that colonoscopy preparation medications should be covered at no cost, many health plans are still not compliant. At the nonfederal level, Jones noted, Kentucky, which has a significant high-risk population, recently became the first state to pass legislation requiring health benefit plans to cover all guideline-recommended CRC exams and lab tests. For its part, the American Gastroenterological Association has also called on payers to eliminate all cost-sharing barriers across the CRC screening continuum. Of note, the study authors said, the higher compliance with the ACA mandate in commercial and Medicaid plans than in Medicare highlights disparities that may disproportionately affect vulnerable older adults. While nearly half of commercial patients and nearly three quarters of Medicaid patients incurred zero out-of-pocket costs, fewer than 17% of Medicare beneficiaries, or 1 in 6, did so. Although these costs may be low relative to the colonoscopy, they nevertheless can deter uptake of preventive screenings, potentially leading to higher CRC incidence and mortality. 'While some patients may be willing to pay modest out-of-pocket costs, any required payment, however small, can serve as a barrier to preventative care, particularly in underserved populations,' they wrote. 'These financial barriers will continue to contribute to widening disparities and hinder progress toward equitable screening outcomes.' In the meantime, said Shah, 'Physicians should advocate now to their representatives in Congress that bowel prep costs should already be covered as part of the ACA.' This study was funded by Sebela Pharmaceuticals, maker of SUFLAVE preparation.
